Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study

Subject’s skin was assessed to be fully clear by Investigator at QRX003 treatment areas

Subject also demonstrated key improvements across all other clinical endpoints, including pruritis

A majority of patients in both Netherton Syndrome studies are expected to be enrolled by the end of August

Both studies are demonstrating an exemplary safety profile for QRX003

Quoin expects its cash runway will extend well into 2H 2024

ASHBURN, Va., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the second quarter of 2023, ended June 30, 2023.

Quoin CEO, Dr. Michael Myers, said, “We are excited to announce positive clinical data for the first subject to complete our ongoing open—label clinical study in Netherton Syndrome patients. While we strongly caution that this data is just from a single subject, the positive nature of the data across all assessed clinical endpoints is indeed noteworthy. With both of our clinical studies on track to having a majority of patients enrolled by the end of August, we look forward to releasing additional clinical data in due course. I am also pleased to announce that across both ongoing clinical studies to date, QRX003 is demonstrating an exemplary safety profile. The generation of this first clinical data is a milestone for Quoin and we hope that it could represent an important step towards providing a safe and effective treatment for such a devastating disease.”

Corporate Highlights –

  • On May 24th 2023, less than 3 months after the first patient had been dosed in its open label clinical trial in Netherton Syndrome patients, Quoin announced that the study had achieved 50% enrollment. The trial is a single arm, open label study, investigating the safety and efficacy of Quoin’s lead candidate, QRX003, in Netherton Syndrome patients who are currently receiving off-label systemic therapy, primarily biologic therapy, and will continue to do so throughout the duration of the study.
  • Today, the company is announcing positive clinical data for the first patient to complete testing in the company’s open-label study in Netherton Syndrome patients. As determined by the clinical site Investigator, the subject’s skin was assessed to be fully clear at the QRX003 treatment sites on completion of the study. The subject’s skin was also assessed to be clear by a well-recognized visual scoring index. Importantly, the subject also had a positive impression of QRX003 across a number of metrics. Furthermore, the patient’s pruritis or itch at the QRX003 treatment site was negligible, representing a substantial improvement from baseline.
  • During the quarter, the company began assessing a number of other potential supportive studies for QRX003 in Netherton Syndrome outside of the US, including one in pediatric patients, and one in pre-identified patients in the Middle East.
  • Also, during the quarter, Quoin continued to advance its two rare disease research programs with Queensland University of Technology for treatment of Scleroderma and Netherton Syndrome and anticipates initiation of clinical testing in Australia for at least one of these programs in 2H 2023.
  • Progress was made during the quarter towards the initiation of proof of concept clinical testing for QRX003 in other indications including SAM Syndrome, Peeling Skin Syndrome and Palmoplantar Keratoderma

Financial Highlights

  • Quoin had approximately $15.4 million in cash, cash equivalents and marketable securities as of June 30, 2023.
  • Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for the quarter ended June 30, 2022, and net loss for the six months ended June 30, 2023 was $4.7 million compared to $4.4 million for the six months ended June 30, 2022.
  • Investors are encouraged to read the Company’s Quarterly Report on Form 10-Q when it is filed with the Securities and Exchange Commission (the “SEC”), which will contain additional details about Quoin’s financial results as of and for the period ended June 30, 2023.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Cautionary Note Regarding Forward Looking Statements

The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 that the Company filed with the SEC. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

For further information:

PCG Advisory
Stephanie Prince
(646) 863-6341

-Tables Follow-

Condensed Consolidated Balance Sheets

  June 30,  December 31, 
Current assets:      
Cash and cash equivalents $4,759,129  $2,860,628 
Investments  10,680,160   9,992,900 
Prepaid expenses  234,226   516,584 
Total current assets  15,673,515   13,370,112 
Prepaid expenses - long term  383,390   383,390 
Intangible assets, net  652,539   704,561 
Total assets $16,709,444  $14,458,063 
Current liabilities:      
Accounts payable $707,935  $605,600 
Accrued expenses  1,834,653   1,175,705 
Accrued interest and financing expense  1,146,251   1,146,251 
Due to officers – short term  725,000   600,000 
Total current liabilities  4,413,839   3,527,556 
Due to officers – long term  3,223,733   3,523,733 
Total liabilities $7,637,572  $7,051,289 
Commitments and contingencies      
Shareholders’ equity:      
Ordinary shares, no par value per share, 500,000,000,000 ordinary shares authorized – 59,233,024,799 (987,217 ADS’s) ordinary shares issued and outstanding at June 30, 2023 and 24,233,024,799 (403,884 ADS’s) at December 31, 2022 $  $ 
Treasury stock, 2,641,693, ordinary shares  (2,932,000)  (2,932,000)
Additional paid in capital  54,230,635   47,855,521 
Accumulated deficit  (42,226,763)  (37,516,747)
Total shareholders’ equity  9,071,872   7,406,774 
Total liabilities and shareholders’ equity $16,709,444  $14,458,063 

Condensed Consolidated Statements of Operations (Unaudited)

  Three months ended June 30,  Six months ended June 30, 
Operating expenses            
General and administrative $1,634,960  $1,941,473  $3,318,777  $3,529,943 
Research and development  625,104   726,694   1,716,837   1,314,263 
Total operating expenses  2,260,064   2,668,167   5,035,614   4,844,206 
Other (income) and expenses            
Forgiveness of accounts payable           (416,000)
Warrant liability (income) expense           (77,237)
Unrealized loss  34,472      14,045    
Interest income  (187,589)     (339,643)   
Total other income  (153,117)     (325,598)  (493,237)
Net loss $(2,106,947) $(2,668,167) $(4,710,016) $(4,350,969)
Loss per ADS            
Loss per ADS            
Basic $(2.13) $(38.91) $(5.79) $(69.90)
Fully-diluted $(2.13) $(38.91) $(5.79) $(69.90)
Weighted average number of ADS’s outstanding            
Basic  987,217   68,573   813,184   62,242 
Fully-diluted  987,217   68,573   813,184   62,242